CR20220343A - Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6 - Google Patents

Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6

Info

Publication number
CR20220343A
CR20220343A CR20220343A CR20220343A CR20220343A CR 20220343 A CR20220343 A CR 20220343A CR 20220343 A CR20220343 A CR 20220343A CR 20220343 A CR20220343 A CR 20220343A CR 20220343 A CR20220343 A CR 20220343A
Authority
CR
Costa Rica
Prior art keywords
cancer
cancer therapeutics
compounds
selective cdk4
inhibitors
Prior art date
Application number
CR20220343A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Jussi Kangasmetsa
Luma G Magalhães
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CR20220343A publication Critical patent/CR20220343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta descripción expone inhibidores selectivos y potentes de CDK 4/6 que muestran una inhibición ventajosa del crecimiento del cáncer, incluso a bajas concentraciones. Esta clase de inhibidores de CDK 4/6 anticancerígenos son compuestos de pirrolopirimidina sustituida de la fórmula 1A, que tienen una porción de ácido graso. Estos compuestos pueden usarse como compuestos farmacéuticos para terapias anticancerígenas y son útiles para el tratamiento, la prevención y/o el mejoramiento del cáncer.
CR20220343A 2019-12-16 2020-12-15 Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6 CR20220343A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948498P 2019-12-16 2019-12-16
US202062966834P 2020-01-28 2020-01-28
PCT/IB2020/061972 WO2021124106A1 (en) 2019-12-16 2020-12-15 Selective cdk4/6 inhibitor cancer therapeutics

Publications (1)

Publication Number Publication Date
CR20220343A true CR20220343A (es) 2023-02-28

Family

ID=76807266

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220343A CR20220343A (es) 2019-12-16 2020-12-15 Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6

Country Status (13)

Country Link
US (1) US20230043357A1 (es)
EP (1) EP4077331A4 (es)
JP (1) JP2023507140A (es)
KR (1) KR20220113985A (es)
CN (1) CN114901666A (es)
AU (1) AU2020405427A1 (es)
BR (1) BR112022011758A2 (es)
CA (1) CA3164617A1 (es)
CR (1) CR20220343A (es)
IL (1) IL293940A (es)
MX (1) MX2022007487A (es)
WO (1) WO2021124106A1 (es)
ZA (1) ZA202207449B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
AU2011240735B2 (en) * 2010-04-13 2015-01-29 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
BR112017021283A2 (pt) 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
DK3302565T3 (da) 2015-06-04 2020-01-02 Pfizer Faste doseringsformer af palbociclib
AU2019251151B2 (en) * 2018-04-09 2022-07-07 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates

Also Published As

Publication number Publication date
EP4077331A4 (en) 2023-12-27
CA3164617A1 (en) 2021-06-24
AU2020405427A1 (en) 2022-07-14
KR20220113985A (ko) 2022-08-17
BR112022011758A2 (pt) 2022-08-30
MX2022007487A (es) 2022-08-04
IL293940A (en) 2022-08-01
CN114901666A (zh) 2022-08-12
WO2021124106A1 (en) 2021-06-24
JP2023507140A (ja) 2023-02-21
ZA202207449B (en) 2023-12-20
EP4077331A1 (en) 2022-10-26
US20230043357A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
WO2017109488A8 (en) Cyanopyrrolidine derivatives as inhibitors for dubs
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
WO2016106331A8 (en) Mutant idh1 inhibitors useful for treating cancer
EA201001618A1 (ru) Ингибиторы syk протеинкиназ
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
AR076053A1 (es) Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
MX2022004035A (es) Inhibidor de diacilglicerol aciltransferasa 2.
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
CR20220667A (es) Derivados de tetrazol como inhibidores de trpa1
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
WO2021076817A3 (en) Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2
PH12021550258A1 (en) Cdk8/19 inhibitors
ZA202207449B (en) Selective cdk4/6 inhibitor cancer therapeutics
MX2022007488A (es) Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.